RedHill Biopharma To Offer ADSs In Public Offering

February 10, 2015 | The Israeli biopharmaceutical company RedHill Biopharma announced that it intends to offer its American Depository Shares (ADS) in an underwritten public offering to cover over-allotments. The company intends to use the proceeds from the offering to continue the research and development of the company’s therapeutic candidates as well as money to go towards potential future acquisitions and general corporate purposes. Wells Fargo will act as the leading book-running manager and Roth Capital Partners will act as the joint book-running manager, along with MLV & Co. RedHill specializes in the development and acquisition of late clinical-stage, proprietary, orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers.